TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alterity Therapeutics ( (AU:ATH) ) has issued an announcement.
Alterity Therapeutics has reported promising results from its ATH434 trials, indicating a strengthened efficacy signal at high doses and a potential market opportunity of USD $2.4 billion in MSA treatment. The company is actively engaging with the FDA to advance ATH434 to Phase 3 trials, with a cash balance of A$54.56M as of September 2025, underscoring its commitment to developing a first-in-class therapy for MSA.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, with a particular emphasis on Multiple System Atrophy (MSA).
YTD Price Performance: 10.0%
Average Trading Volume: 10,503,379
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$119.6M
For a thorough assessment of ATH stock, go to TipRanks’ Stock Analysis page.